Croft-Leominster’s Eli Lilly LLY Stock Holding History

Croft-Leominster’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,750	Closed	-$374K	–	148
2016 Q2	$374K	Hold	4,750	–	–	0.08%	120
2016 Q1	$342K	Hold	4,750	–	–	0.08%	120
2015 Q4	$400K	Hold	4,750	–	–	0.09%	115
2015 Q3	$398K	Hold	4,750	–	–	0.09%	105
2015 Q2	$397K	Hold	4,750	–	–	0.08%	111
2015 Q1	$345K	Buy	4,750 +600	+14%	+$42.7K	0.06%	120
2014 Q4	$286K	Hold	4,150	–	–	0.05%	137
2014 Q3	$269K	Hold	4,150	–	–	0.05%	139
2014 Q2	$258K	Sell	4,150 -232	-5%	-$13.8K	0.04%	147
2014 Q1	$257K	Hold	4,382	–	–	0.04%	144
2013 Q4	$223K	Hold	4,382	–	–	0.03%	163
2013 Q3	$221K	Hold	4,382	–	–	0.04%	157
2013 Q2	$215K	Buy	+4,382	New	+$238K	0.03%	152

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Croft-Leominster's LLY Position: Q3 2016 in Review

Croft-Leominster sold out of Eli Lilly (LLY) in Q3 2016, closing a stake of 4,750 shares — an estimated $374K sold.

Croft-Leominster first reported a position in LLY in Q2 2013 and held it in 13 quarters. The position peaked at $400K in Q4 2015. 1,176 funds tracked by Wall St. Rank hold LLY as of Q3 2016.

Croft-Leominster reported no remaining Eli Lilly position as of Q3 2016 after selling out during the quarter.
Croft-Leominster sold 4,750 Eli Lilly shares in Q3 2016, an estimated $374K.
Croft-Leominster first reported a position in Eli Lilly in Q2 2013 and held it in 13 quarters.
Croft-Leominster's Eli Lilly position peaked at $400K in Q4 2015.
1,176 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2016.

Based on Croft-Leominster's 13F filing for Q3 2016, filed 15 Nov 2016.